This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n13http://linked.opendata.cz/resource/domain/vavai/projekt/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/ontology/domain/vavai/
n16http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F68407700%3A21460%2F10%3A00228139%21RIV15-MSM-21460___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F68407700%3A21460%2F10%3A00228139%21RIV15-MSM-21460___
rdf:type
n15:Vysledek skos:Concept
dcterms:description
Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease. Time-consuming imaging methods, examination of cerebrospinal fluid or tumour tissue and assays for hormones and tumour markers have been used for cancer diagnosis. However, no specific marker for diagnosis of childhood solid tumours has been discovered yet. In this study, metallothionein (MT) was evaluated as a prospective marker for such diseases. Serum metallothionein levels of patients with childhood solid tumours were determined using differential pulse voltammetry - Brdicka reaction. A more than 5-fold increase in the amount of metallothionein was found in sera of patients suffering from cancer disease, compared with those in sera of healthy donors. The average metallothionein level in the sera of healthy volunteers was 0.5 +/- 0.2 mu mol.dm(-3) and was significantly different (P<0.05, determined using the Schefe test) from the average MT level found in serum samples of patients suffering from childhood solid tumours (3.4 +/- 0.8 mu mol.dm(-3)). Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours. Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease. Time-consuming imaging methods, examination of cerebrospinal fluid or tumour tissue and assays for hormones and tumour markers have been used for cancer diagnosis. However, no specific marker for diagnosis of childhood solid tumours has been discovered yet. In this study, metallothionein (MT) was evaluated as a prospective marker for such diseases. Serum metallothionein levels of patients with childhood solid tumours were determined using differential pulse voltammetry - Brdicka reaction. A more than 5-fold increase in the amount of metallothionein was found in sera of patients suffering from cancer disease, compared with those in sera of healthy donors. The average metallothionein level in the sera of healthy volunteers was 0.5 +/- 0.2 mu mol.dm(-3) and was significantly different (P<0.05, determined using the Schefe test) from the average MT level found in serum samples of patients suffering from childhood solid tumours (3.4 +/- 0.8 mu mol.dm(-3)). Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours.
dcterms:title
Serum metallothionein in newly diagnosed patients with childhood solid tumours Serum metallothionein in newly diagnosed patients with childhood solid tumours
skos:prefLabel
Serum metallothionein in newly diagnosed patients with childhood solid tumours Serum metallothionein in newly diagnosed patients with childhood solid tumours
skos:notation
RIV/68407700:21460/10:00228139!RIV15-MSM-21460___
n3:aktivita
n10:Z n10:I n10:P
n3:aktivity
I, P(GAP301/10/0356), P(GP301/09/P436), P(NS10200), Z(MSM0021620808)
n3:cisloPeriodika
4
n3:dodaniDat
n7:2015
n3:domaciTvurceVysledku
n8:3778924
n3:druhVysledku
n14:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
287032
n3:idVysledku
RIV/68407700:21460/10:00228139
n3:jazykVysledku
n19:eng
n3:klicovaSlova
metallothionein; cancer; serum; Brdicka reaction; marker
n3:klicoveSlovo
n9:metallothionein n9:cancer n9:Brdicka%20reaction n9:serum n9:marker
n3:kodStatuVydavatele
PL - Polská republika
n3:kontrolniKodProRIV
[EFB14937A181]
n3:nazevZdroje
ACTA BIOCHIMICA POLONICA
n3:obor
n11:CE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
10
n3:projekt
n13:GAP301%2F10%2F0356 n13:NS10200 n13:GP301%2F09%2FP436
n3:rokUplatneniVysledku
n7:2010
n3:svazekPeriodika
57
n3:tvurceVysledku
Majzlik, P. Prusa, R. Kukačka, Jiří Stiborova, M. Krizek, R. Adam, V. Kruseova, J. Krizkova, S. Eckschlager, T. Masarik, M.
n3:wos
000285726300023
n3:zamer
n16:MSM0021620808
s:issn
0001-527X
s:numberOfPages
6
n18:organizacniJednotka
21460